Is Brexucabtagene Autoleucel approved by the FDA?

Yes, brexucabtagene autoleucel, marketed under the brand name Tecartus, is FDA approved. Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.

What is Brexucabtagene Autoleucel?

Brexucabtagene autoleucel is an immunotherapy medication specifically designed to treat mantle cell lymphoma (MCL) in adults. This treatment is particularly used when other therapies have not been effective or have ceased to work. The drug involves modifying a patient's own white blood cells to target and destroy cancer cells.

How Brexucabtagene Autoleucel Works

Brexucabtagene autoleucel is created using the patient’s white blood cells, which are extracted through a procedure called leukapheresis. These cells are then genetically modified in a laboratory to produce chimeric antigen receptors (CARs) on their surface. These CAR-positive cells are infused back into the patient, where they seek out and destroy cancer cells.

Administration and Dosage

Brexucabtagene autoleucel is administered intravenously in a hospital or clinical setting by healthcare professionals trained in CAR-T cell therapy. The treatment process involves several key steps:

1. Leukapheresis: Blood is drawn from the patient, and white blood cells are separated and collected.
2. Cell Modification: The collected white blood cells are sent to a laboratory where they are genetically engineered to produce CARs.
3. Chemotherapy: Before the modified cells are infused back into the patient, a short course of chemotherapy is given to prepare the body.
4. Infusion: The CAR-positive T cells are infused into the patient.

Potential Side Effects

Like all medications, brexucabtagene autoleucel can cause side effects, some of which can be serious. Common side effects include:

• Cytokine Release Syndrome (CRS): This is a common but serious side effect characterized by fever, chills, trouble breathing, and other symptoms. Immediate medical intervention is required if CRS occurs.
• Infections: Increased susceptibility to infections due to the effect on the immune system.
• Neurological Toxicity: Symptoms can include severe drowsiness, trouble speaking or writing, confusion, seizures, and difficulty with daily activities.

Precautions and Warnings

Patients should be carefully monitored for infections, neurological symptoms, and signs of CRS. The treatment is not suitable for patients with active infections or certain pre-existing conditions. Pregnant or breastfeeding women should consult their healthcare provider about potential risks.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!